ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) posted its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04).

Shares of ImmunoCellular Therapeutics (NYSEMKT:IMUC) opened at 0.0843 on Monday. ImmunoCellular Therapeutics has a 1-year low of $0.08 and a 1-year high of $0.53. The stock’s market cap is $10.79 million. The stock’s 50 day moving average price is $0.10 and its 200-day moving average price is $0.18.

Earnings History for ImmunoCellular Therapeutics (NYSEMKT:IMUC)

A hedge fund recently raised its stake in ImmunoCellular Therapeutics stock. Sabby Management LLC boosted its position in ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,452,128 shares of the company’s stock after buying an additional 40,757 shares during the period. Sabby Management LLC owned about 4.78% of ImmunoCellular Therapeutics worth $1,025,000 at the end of the most recent quarter.

A number of research analysts have commented on the stock. Maxim Group cut shares of ImmunoCellular Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded shares of ImmunoCellular Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Thursday, August 25th.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Stock Ratings for ImmunoCellular Therapeutics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd. and related stocks with our FREE daily email newsletter.